Teva signs 5-year contract to supply DOD with adenovirus vaccine

When picturing the various dangers faced by military members, basic training isn't the first to come to mind. But basic training facilities are the right environment--close quarters and high-stress, according to a WDBJ 7 report--for respiratory illness caused by adenovirus to thrive and spread. Enter Teva Pharmaceutical ($TEVA), which will supply military basic training camps with live, oral vaccines for adenovirus type 4 and type 7 through December 2019. The company has a 5-year contract with the Department of Defense, under which it anticipates supplying 200,000 to 250,000 doses per year, Teva spokeswoman Michelle Larkin told FierceVaccines in an email. WDBJ 7 video | Roanoke Times story

Suggested Articles

BN will use its proprietary MVA-BN platform to develop a vaccine against three strains of the potentially deadly mosquito-borne virus.

BN's cancer vaccine CV301 is already under evaluation with Keytruda in NSCLC and with Tecentriq in bladder cancer.

The two new grants will support development of universal flu and malaria vaccines leveraging CureVac’s RNActive mRNA-based platform.